SENESTECH INC (SNES)
US81720R5054 - Common Stock
SNES gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. SNES has a bad profitability rating. Also its financial health evaluation is rather negative. SNES shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
SNES had negative earnings in the past year.
In the past year SNES has reported a negative cash flow from operations.
In the past 5 years SNES always reported negative net income.
In the past 5 years SNES always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -149.74%, SNES is doing worse than 84.82% of the companies in the same industry.
Looking at the Return On Equity, with a value of -182.47%, SNES is doing worse than 69.11% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -149.74% | ||
| ROE | -182.47% | ||
| ROIC | N/A |
ROA(3y)-106.9%
ROA(5y)-132.23%
ROE(3y)-129.16%
ROE(5y)-198.69%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SNES has a Gross Margin of 50.15%. This is in the better half of the industry: SNES outperforms 61.26% of its industry peers.
In the last couple of years the Gross Margin of SNES has grown nicely.
SNES does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 50.15% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y17.7%
2. Health
2.1 Basic Checks
SNES does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SNES has more shares outstanding
The number of shares outstanding for SNES has been increased compared to 5 years ago.
The debt/assets ratio for SNES is higher compared to a year ago.
2.2 Solvency
SNES has an Altman-Z score of -43.29. This is a bad value and indicates that SNES is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of SNES (-43.29) is worse than 92.67% of its industry peers.
SNES has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
SNES has a Debt to Equity ratio of 0.05. This is comparable to the rest of the industry: SNES outperforms 51.83% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -43.29 |
ROIC/WACCN/A
WACC9.38%
2.3 Liquidity
A Current Ratio of 6.32 indicates that SNES has no problem at all paying its short term obligations.
SNES has a Current ratio of 6.32. This is in the better half of the industry: SNES outperforms 72.25% of its industry peers.
SNES has a Quick Ratio of 4.92. This indicates that SNES is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 4.92, SNES is in the better half of the industry, outperforming 68.06% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.32 | ||
| Quick Ratio | 4.92 |
3. Growth
3.1 Past
SNES shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 84.67%, which is quite impressive.
SNES shows a strong growth in Revenue. In the last year, the Revenue has grown by 37.58%.
SNES shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 31.80% yearly.
EPS 1Y (TTM)84.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.33%
Revenue 1Y (TTM)37.58%
Revenue growth 3Y66.17%
Revenue growth 5Y31.8%
Sales Q2Q%33.89%
3.2 Future
The Earnings Per Share is expected to grow by 25.71% on average over the next years. This is a very strong growth
SNES is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 85.15% yearly.
EPS Next Y96.36%
EPS Next 2Y40.89%
EPS Next 3Y25.71%
EPS Next 5YN/A
Revenue Next Year75.15%
Revenue Next 2Y87.78%
Revenue Next 3Y85.15%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
SNES reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SNES. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as SNES's earnings are expected to grow with 25.71% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.89%
EPS Next 3Y25.71%
5. Dividend
5.1 Amount
No dividends for SNES!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SENESTECH INC
NASDAQ:SNES (12/18/2024, 12:39:42 PM)
3.22
-0.47 (-12.74%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap3.32M
Analysts
Price Target
Short Float %
Short Ratio
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -149.74% | ||
| ROE | -182.47% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 50.15% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 6.32 | ||
| Quick Ratio | 4.92 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)84.67%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y96.36%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)37.58%
Revenue growth 3Y66.17%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y